ストックスクリーナーアプリを入手
28.41
0.85%
0.24
前日終値:
$28.17
開ける：
$28.42
24時間の取引高:
499.89K
Relative Volume:
1.89
時価総額：
$470.77M
収益：
$99.61M
当期純損益:
$-153.60M
株価収益率:
-1.7273
EPS:
-16.4479
ネットキャッシュフロー:
$-152.14M
1週間 パフォーマンス:
+8.89%
1か月 パフォーマンス:
-27.10%
6か月 パフォーマンス:
+211.17%
1年 パフォーマンス:
+259.57%
1日の値動き範囲:
$27.66
$30.62
1週間の範囲:
$26.29
$31.46
52週間の値動き範囲:
$6.736
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
名前
Sutro Biopharma Inc
セクター
電話
650-392-8412
住所
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
28.41 | 500.43M | 99.61M | -153.60M | -152.14M | -16.45 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-07 | 開始されました | Leerink Partners | Outperform |
| 2026-03-24 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-03-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-05-08 | 開始されました | BofA Securities | Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-06 | 開始されました | Oppenheimer | Outperform |
| 2023-03-21 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2021-06-18 | 開始されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-09-02 | 開始されました | Jefferies | Buy |
| 2020-07-16 | 開始されました | Wells Fargo | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-10-07 | 開始されました | BTIG Research | Buy |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-22 | 開始されました | Wedbush | Outperform |
すべてを表示
Sutro Biopharma Inc (STRO) 最新ニュース
This drug 'gave our daughter another chance' — now a nonprofit's deal hopes to secure its use for years to come - The Business Journals
Sutro Biopharma (STRO) Surges Over 9% as Buyers Test Key Resistance at $30.54Elliott Wave Entry - newsline.com
Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities - Moomoo
Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director granted 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike - Stock Titan
Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027 - Stock Titan
Sutro Biopharma (STRO) director receives 10,000-share stock option grant - Stock Titan
[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Sutro Biopharma (STRO) director receives grant of 10,000 stock options - Stock Titan
Director at Sutro Biopharma (STRO) receives 10,000 stock options as equity grant - Stock Titan
Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results - Stock Titan
Sutro Biopharma Surges 5.52% – Testing Key Resistance at $30.11 After Strong SessionAdvance Decline Volume - newsline.com
Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings - Stock Titan
STRO Q1 2026 Earnings: Narrower Loss Beats Estimates as Sutro Biopharma Advances PipelineTech Earnings Analysis - The Legal Advocate
Barclays Initiates a Buy Rating on Sutro Biopharma (STRO) - The Globe and Mail
STRO Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target - marketscreener.com
Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46% - simplywall.st
News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts - Yahoo Finance
Barclays initiates Sutro Biopharma stock with overweight rating By Investing.com - Investing.com Australia
Barclays initiates Sutro Biopharma stock with overweight rating - Investing.com
Sutro Biopharma (STRO) Surges 6%: Key Levels and Market DynamicsEarnings Beat Stocks - The Legal Advocate
H.C. Wainwright Remains a Buy on Sutro Biopharma (STRO) - The Globe and Mail
H.C. Wainwright Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Sutro Biopharma CEO unveils expanding ADC pipeline and key cancer partnerships - Traders Union
Sutro Biopharma (STRO) price target increased by 1,325.54% to 39.05 - MSN
Sutro Biopharma (STRO) Consolidates Near Resistance: Biotech Stock Shows Modest GainsSocial Trading Insights - Newser
Sutro Biopharma (STRO) Sees Minor Dip, Holds Above Key SupportWyckoff Accumulation - Newser
STRO SEC FilingsSutro Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
US$47.10That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results - Yahoo Finance
Update: Sutro Biopharma Shares Rise After Q1 Loss Narrows - Moomoo
STRO Maintained by HC Wainwright & Co. -- Price Target Raised to $50 - GuruFocus
STRO Upgraded by Wedbush -- Price Target Raised to $60 - GuruFocus
Is Sutro Biopharma (STRO) 189.6% Overvalued After Q1 2026? EPS b - GuruFocus
Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 14% Upside - TradingView
Sutro Biopharma (STRO) affiliates disclose 1.06M shares; ownership details - Stock Titan
Kynam Capital reports 5.27% stake in Sutro Biopharma (NASDAQ: STRO) - Stock Titan
STRO Maintained by Leerink Partners -- Price Target Raised to $4 - GuruFocus
Sutro Biopharma Shares Rise After Q1 Loss Narrows - marketscreener.com
Gemini Space posts upbeat Q1 results, joins Figma, Sutro Biopharma and other big stocks moving higher on Friday - MSN
Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22 - Moomoo
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday - Benzinga
Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside - TradingView
Sutro Biopharma (STRO) Q1 Revenue Surpasses Expectations - GuruFocus
Sutro Biopharma Q1 Loss Narrows, Revenue Declines - Moomoo
Sutro Biopharma (NASDAQ: STRO) narrows Q1 loss and boosts cash with $110M share sale - Stock Titan
Sutro Biopharma releases first quarter financials and updates business outlook - Traders Union
Net loss narrows as Sutro Biopharma (NASDAQ: STRO) boosts cash into 2028 - Stock Titan
Sutro Biopharma Inc (STRO) 財務データ
収益
当期純利益
現金流量
EPS
Sutro Biopharma Inc (STRO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 04 '26 |
Option Exercise |
0.00 |
675 |
0 |
10,025 |
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):